JPRN-UMIN000038263已完成未知
A using test for four continuous weeks of C-271 in babies - A using test for four continuous weeks of C-271 in babies
Inforward, inc EBISU skin research center0 个研究点目标入组 60 人开始时间: 2021年8月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 28days-old 至 365days-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Premature babies. 2)Subjects with birth weight <2,500g. 3)Subjects who have severe eczema infantile. 4)Subjects who have skin symptom such as atopic dermatitis. 5)Subjects who have trauma on the part that uses the test sample. 6)Subjects who have possibility to be exposed to many quantity of sunlight during implementing the test. 7)Subjects who are participating in clinical tests and use tests that apply cosmetic, quasi-drugs and others. 8)Subjects who have allergic symptoms against external medicine, cosmetic, quasi-drugs and others in the past. 9)Subjects who have medical history of serious liver dysfuction, kidney dysfuction and myocardial infarction. 10)Subject who are visiting the hospital regulary for receiving the medical treatment due to the diseases. 11)Subjects who have their family they are working at cosmetic companies and pharmaceutical companies. 12)Others, subjects who have been determined that he/she is ineligible by investigators.
研究者
相似试验
已完成
不适用
A using test for four continuous weeks of SC1722 against babiesJPRN-UMIN000032333Inforward, inc EBISU skin research center60
招募中
1 期
VACCINE EFFECTIVENESS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE CAP USING A TEST-NEGATIVE DESIGVACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIAMedDRA version: 20.1Level: LLTClassification code: 10010120Term: Community acquired pneumonia Class: 10021881CTIS2023-507293-40-00Pfizer Inc.12,500
招募中
4 期
Assessing the differential benefits of various anti diabetic agents among individuals with novel subtypes of diabetesCTRI/2021/11/037753SV Private Limited
招募中
4 期
Study to assess safety, tolerability and effectiveness in patients with severe dementia exposed to exeloCTRI/2018/02/011948ovartis India Limited
进行中(未招募)
不适用
A 4-week trial evaluating the efficacy, safety, and tolerability of GRT6005, a new centrally acting analgesic, in subjects with moderate to severe pain due to osteoarthritis of the knee.EUCTR2010-022556-23-ATGrünenthal GmbH170
